|Ms. Joanne Patterson||CEO, Director & Member of Medical Advisory Board||273.75k||N/A||N/A|
|Mr. Craig Weller||COO & Member of Medical Advisory Board||273.75k||N/A||N/A|
|Mr. George Livery||Exec. Chairman||N/A||N/A||1967|
|Dr. Adele Hosseini||Chief Scientific Officer & Member of Medical Advisory Board||N/A||N/A||N/A|
|Mr. Stephen Thompson||Exec. Director||N/A||N/A||N/A|
BOD Australia Limited operates as a developer, manufacturer, distributor, and marketer of plant-based medicinal cannabis, health and supplement products, and cosmetic solutions primarily in Australia. Its medicines portfolio includes Enterofytol for treating irritable bowel syndrome; and SediStress, which is used for the reduction of stress and anxiety. The company distributes its products through a channel network of approximately 900 pharmacies. It offers products under the SediStress, BIOEFFECT, PINPOINT, Flexofytol, Enterofytol, MamaCare, and Pommade Devine brands. Bod Australia Limited has a research collaboration agreement with Cannabis Access Clinics. The company is based in Double Bay, Australia.
Bod Australia Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.